Vertex Pharmaceuticals Inc VRTX last week announced that the Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR) had met its primary endpoint.The company announced that the FDA had approved Alyftrek (or vanzacaftor triple) in cystic fibroris (CF) six years and older, in-line with expectations, according to Goldman Sachs.Analyst Salveen Richter maintained a Buy rating for Vertex Pharmaceuticals and price target of $602.The Vertex Pharmaceuticals Thesis: During the initial launch of Alyft ...